Martin Nicholas to Male
This is a "connection" page, showing publications Martin Nicholas has written about Male.
Connection Strength
0.123
-
Update in the treatment of high-grade Gliomas. Neurol Clin. 2013 Aug; 31(3):847-67.
Score: 0.023
-
Bevacizumab for glioblastoma multiforme after traumatic subarachnoid hemorrhage. J Clin Neurosci. 2012 Sep; 19(9):1310-1.
Score: 0.022
-
Glioblastoma multiforme: evidence-based approach to therapy. Expert Rev Anticancer Ther. 2007 Dec; 7(12 Suppl):S23-7.
Score: 0.016
-
Emerging therapies for malignant glioma. Expert Rev Anticancer Ther. 2007 Dec; 7(12 Suppl):S29-36.
Score: 0.016
-
Association between hospital volume and receipt of treatment and survival in patients with glioblastoma. J Neurooncol. 2017 Dec; 135(3):529-534.
Score: 0.008
-
Clinical neuro-oncology formal education opportunities for medical students in the United States and Canada. World Neurosurg. 2014 Dec; 82(6):938-44.
Score: 0.006
-
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011 Jun; 13(6):660-8.
Score: 0.005
-
Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist. 2010; 15(12):1329-34.
Score: 0.005
-
Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011 Jan; 13(1):143-51.
Score: 0.005
-
A phase I study of continuous infusion cilengitide in patients with solid tumors. Invest New Drugs. 2012 Apr; 30(2):604-10.
Score: 0.005
-
Prevention of neural allograft rejection in the mouse following in vivo depletion of L3T4+ but not LYT-2+ T-lymphocytes. Prog Brain Res. 1990; 82:161-7.
Score: 0.005
-
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009 Oct 01; 27(28):4733-40.
Score: 0.005
-
Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies. Clin Cancer Res. 1999 Jun; 5(6):1325-30.
Score: 0.002